In last trading session, Arcturus Therapeutics Holdings Inc (NASDAQ:ARCT) saw 0.67 million shares changing hands with its beta currently measuring 2.68. Company’s recent per share price level of $27.27 trading at $0.75 or 2.83% at ring of the bell on the day assigns it a market valuation of $734.38M. That closing price of ARCT’s stock is at a discount of -60.65% from its 52-week high price of $43.81 and is indicating a premium of 35.75% from its 52-week low price of $17.52. Taking a look at company’s average trading volume volume of 505.03K if we extend that period to 3-months.
Arcturus Therapeutics Holdings Inc (NASDAQ:ARCT) trade information
Upright in the green during last session for gaining 2.83%, in the last five days ARCT remained trading in the green while hitting it’s week-highest on Wednesday, 05/01/24 when the stock touched $27.27 price level, adding 4.05% to its value on the day. Arcturus Therapeutics Holdings Inc’s shares saw a change of -13.51% in year-to-date performance and have moved 2.71% in past 5-day. Arcturus Therapeutics Holdings Inc (NASDAQ:ARCT) showed a performance of -10.88% in past 30-days.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Arcturus Therapeutics Holdings Inc (ARCT) estimates and forecasts
Statistics highlight that Arcturus Therapeutics Holdings Inc is scoring comparatively lower than the scores of other players of the relevant industry. The company added 45.29% of value to its shares in past 6 months, showing an annual growth rate of -42.21% while that of industry is 12.80. Apart from that, the company came lowering its revenue forecast for fiscal year 2024. This year revenue growth is estimated to fall -13.90% from the last financial year’s standing.
8 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 17.54M for the same. And 8 analysts are in estimates of company making revenue of 23.8M in the next quarter. Company posted 79.73M and 10.52M of sales in current and next quarters respectively a year earlier.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 12.40% during past 5 years.
ARCT Dividends
Arcturus Therapeutics Holdings Inc is more likely to be releasing its next quarterly report in June and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.
